Literature DB >> 2267920

Anti-infective factors in preterm human colostrum.

N B Mathur1, A M Dwarkadas, V K Sharma, K Saha, N Jain.   

Abstract

Feeding of the infection prone preterm neonate with concentrated immunologically active ingredients in the form of colostrum may have even more significant clinical implications than in the full term infants. The scarcity of knowledge on anti-infective factors in colostrum of mothers delivering prematurely prompted us to carry out this study. Colostrum was collected and analysed from 25 mothers delivering prematurely (Study group) and 10 delivering at term (Control group). Major anti-infective factors namely IgA, IgG, IgM, lactoferrin and lysozyme were quantitated and total cell, macrophage, lymphocyte and neutrophil counts were performed. The mean concentrations of IgA, lysozyme and lactoferrin of preterm colostrum were significantly higher than in full term colostrum (p less than 0.001). IgG and IgM were found to be similar in both groups. The absolute counts of total cells, macrophages, lymphocytes and neutrophils were found to be significantly higher in the preterm colostrum as compared to the full term colostrum (p less than 0.001). Though in both the groups IgA was the predominant immunoglobulin, the mean percentage of IgA in the study group was significantly higher as compared to the control group. Degree of prematurity did not have any influence on the anti-infective protein levels in colostrum. However total cells and macrophages were significantly higher in colostrum of mothers delivering severely preterm babies.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2267920     DOI: 10.1111/j.1651-2227.1990.tb11380.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  15 in total

1.  Killing of gram-negative bacteria by lactoferrin and lysozyme.

Authors:  R T Ellison; T J Giehl
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

Review 2.  Factors affecting lactoferrin concentration in human milk: how much do we know?

Authors:  Aasith Villavicencio; Maria S Rueda; Christie G Turin; Theresa J Ochoa
Journal:  Biochem Cell Biol       Date:  2016-08-04       Impact factor: 3.626

3.  Immunologic Factors in Human Milk and Disease Prevention in the Preterm Infant.

Authors:  Katherine E Gregory; W Allan Walker
Journal:  Curr Pediatr Rep       Date:  2013-12

4.  Generation of bi-transgenic pigs overexpressing human lactoferrin and lysozyme in milk.

Authors:  Dan Cui; Jia Li; Linlin Zhang; Shen Liu; Xiao Wen; Qiuyan Li; Yaofeng Zhao; Xiaoxiang Hu; Ran Zhang; Ning Li
Journal:  Transgenic Res       Date:  2014-09-19       Impact factor: 2.788

5.  Inactivation of gram-negative bacteria by lysozyme, denatured lysozyme, and lysozyme-derived peptides under high hydrostatic pressure.

Authors:  B Masschalck; R Van Houdt; E G Van Haver; C W Michiels
Journal:  Appl Environ Microbiol       Date:  2001-01       Impact factor: 4.792

6.  Breastfeeding.

Authors:  N B Mathur; Dhulika Dhingra
Journal:  Indian J Pediatr       Date:  2013-08-01       Impact factor: 1.967

Review 7.  Does human milk reduce infection rates in preterm infants? A systematic review.

Authors:  A de Silva; P W Jones; S A Spencer
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-11       Impact factor: 5.747

8.  A pilot study to determine the safety and feasibility of oropharyngeal administration of own mother's colostrum to extremely low-birth-weight infants.

Authors:  Nancy A Rodriguez; Paula P Meier; Maureen W Groer; Janice M Zeller; Janet L Engstrom; Lou Fogg
Journal:  Adv Neonatal Care       Date:  2010-08       Impact factor: 1.968

Review 9.  Oropharyngeal administration of colostrum to extremely low birth weight infants: theoretical perspectives.

Authors:  N A Rodriguez; P P Meier; M W Groer; J M Zeller
Journal:  J Perinatol       Date:  2008-09-04       Impact factor: 2.521

10.  Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment.

Authors:  K Yamauchi; M Tomita; T J Giehl; R T Ellison
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.